Trial Profile

A pivotal Phase IIIb study of ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 02 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pipamperone (Primary) ; Antidepressants
Indications Major depressive disorder
Focus Registrational; Therapeutic Use
Sponsors ANeuroTech

Most Recent Events

31 Jan 2024 According to an ANeuroTech media release, company plans to begin a pivotal Phase IIIb clinical trial of ANT-01 in 2024.
05 Jun 2023 According to an ANeuroTech media release, the trial plans to recruit more than 500 patients at sites in the US, Europe and South America.
05 Jun 2023 According to an ANeuroTech media release, this study expects to begin later this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com